newsfilter
← Earnings
Earnings Releases·

Xilio Therapeutics — Third Quarter 2026 Earnings Summary

Xilio Therapeutics initiated the first patient dosing in its Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific antibody, in patients with metastatic non-small cell lung cancer. The company plans to submit investigational new drug applications for its masked T cell engager programs, XTX602 and XTX701, in the fourth quarter of 2027. For the third quarter ended September 30, 2026, Xilio reported cash and cash equivalents of $122.2 million and a net loss of $5.9 million. Based on current operating plans, the company anticipates its cash reserves will fund operations into the first quarter of 2028.

Company
XILIO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology